ORCID Profile
0000-0001-8312-1219
Current Organisations
Utrecht University
,
Hubrecht Institute
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 10-07-2022
DOI: 10.1111/IMJ.15831
Abstract: Gout is a common chronic inflammatory disorder due to monosodium urate deposition, which results in severe inflammatory arthritis. It is particularly common in those of Māori or Pacific Islander heritage. There is a significant number of this at‐risk ethnic group in western Sydney. To determine the healthcare burden of gout in Western Sydney. We characterised patients managed in the emergency departments (EDs) of the four Western Sydney Local Health District (WSLHD) hospitals and those admitted for gout as the primary or secondary diagnosis from 1 January 2017 to 31 December 2018. There were 472 patients managed in ED on 552 occasions at a direct cost to the LHD of A$367 835. Those of Māori or Pacific Islander ethnicity comprised 25.2% ( n = 119/472), while half ( n = 39/80) of those managed in ED for gout on two or more occasions were of Māori or Pacific Islander ethnicity. Overall, 310 patients were admitted with gout as the principal diagnosis on 413 occasions at a cost of A$1.73 million. Seventy‐five (24.2%) of the 310 patients were of Māori or Pacific Islander heritage. A total of 584 WSLHD inpatients had gout as a secondary diagnosis. This was associated with 714 admissions. The disproportionately large healthcare burden of gout in Western Sydney from the relatively small Māori and Pacific Islander population needs attention. Urgent culturally appropriate interventions to address gout are required to address this inequality.
Publisher: Springer Science and Business Media LLC
Date: 21-11-2015
Publisher: Wiley
Date: 18-12-2019
Publisher: S. Karger AG
Date: 11-12-2010
DOI: 10.1159/000321988
Abstract: Sinusoidal forces with frequencies of 100 and 500 Hz and initial positive or negative polarities were delivered to the mastoids and Fz in normal subjects. We investigated whether the cVEMPs and oVEMPs evoked were sensitive to the polarity (phase) of vibration. With mastoid stimulation at 100 Hz, medial head acceleration produced cVEMPs with earlier latency (15.5 ms) than lateral acceleration (19.7 ms) and oVEMPs with later latency (13.8 ms) than lateral acceleration (10.6 ms). As the stimulus frequency increased, the difference in latency decreased, but was still present at 500 Hz. A similar pattern occurred following stimulation at Fz. Our results show that the initial direction of bone-conducted vibration affects both cVEMP and oVEMP properties even at relatively high frequencies.
Publisher: AVES YAYINCILIK A.Ş.
Date: 10-08-2020
Publisher: Wiley
Date: 23-05-2021
DOI: 10.1111/IMJ.15390
Abstract: Rheumatoid arthritis (RA) is a common autoimmune disease where methotrexate (MTX) is widely used as the first‐line therapy. The combination of RA and MTX is associated with lymphoproliferative disorders (LPD). RA patients with Epstein–Barr virus (EBV) have impaired T‐lymphocyte function, thus allowing an overgrowth of EBV‐positive lymphoblastoid cells. We examined the association of EBV with LPD in immunosuppressed RA patients, particularly those treated with MTX. To review the relationship between RA, EBV‐associated LPD and MTX use. We reported two cases of RA patients with long‐term MTX treatment who subsequently developed EBV‐positive LPD, followed by a review of the relevant literature. Compared with normal population, RA patients have a higher risk of lymphoma, with diffuse large B‐cell lymphoma being the most common subtype. MTX withdrawal can lead to lymphoma regression. Other biological therapies, such as abatacept and tocilizumab, are not associated with increased EBV‐positive lymphoma diagnosis in RA patients. The association between EBV, lymphoma and MTX highlights the need to consider reducing or stopping MTX in patients who have had stable RA for many years.
Publisher: Public Library of Science (PLoS)
Date: 20-02-2008
Publisher: Springer Science and Business Media LLC
Date: 15-09-2023
No related grants have been discovered for Ken Cai.